글로벌 제약 연속 제조 시장 – 2031년까지의 산업 동향 및 예측

제약 연속 제조 시장 분석 및 규모

글로벌 제약 연속 제조 시장은 비용 효율성, 효율성 및 규제 지원에 의해 추진됩니다. 연속 제조는 간소화된 생산 프로세스, 일관된 제품 품질 및 더 빠른 출시 시간을 보장합니다. 정제 생산, 과립화, 코팅 및 통합 공정 제어에 적용되어 전 세계 제약 회사에 공급망 통합 및 향상된 추적성을 제공합니다.

Data Bridge Market Research는 글로벌 제약 연속 제조 시장이 2023년에 28억 6천만 달러 규모로 성장했으며, 2031년에는 53억 5천만 달러 규모로 성장하여 2024년에서 2031년까지 연평균 성장률 8.16%를 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 수입/수출 분석, 가격 분석, 생산 소비 분석, 특허 분석, 소비자 행동이 포함되어 있습니다.  

보고 범위 및 시장 세분화      

시장 정의

제약 연속 제조는 제약이 중단 없이 연속적으로 제조되는 생산 방법입니다. 여기에는 정제, 캡슐 및 기타 투여 형태와 같은 완제품으로 원료를 간소화되고 통합적으로 처리하는 것이 포함됩니다.

글로벌 제약 연속 제조 시장 역학

운전자

• 제약품의 연속 제조로 비용 절감이 용이해집니다.  

제약 분야의 연속 제조는 운영 최적화, 노동 요구 사항 감소, 에너지 소비 감소, 재료 낭비 최소화를 통해 비용 절감을 용이하게 합니다. 중단 없는 프로세스는 효율성과 자원 활용을 향상시켜 제약 회사의 수익성과 경쟁력을 개선합니다. 이러한 이점은 최종 이익과 시장 지위를 향상하려는 회사에 전략적 선택이 됩니다.

• 연속 제조로 자원 효율성이 향상됩니다.

연속 제조는 생산 주기 사이의 가동 중지 시간을 최소화하고, 장비 활용을 최적화하며, 수동 개입의 필요성을 줄임으로써 자원 효율성을 향상시킵니다. 연속 프로세스를 통해 제약 회사는 운영을 간소화하고, 낭비를 줄이고, 자원을 보다 효과적으로 활용할 수 있습니다. 자동화와 고급 제어 시스템을 통합함으로써 연속 제조는 매개변수의 정확한 모니터링과 조정을 보장하여 제품 품질과 일관성을 유지하면서 자원 활용을 극대화하고 궁극적으로 전반적인 운영 효율성을 개선합니다.

기회

• 규제 기관에서 연속 제조 도입을 장려

Regulatory agencies, such as the FDA and EMA, are encouraging the adoption of continuous manufacturing to enhance drug quality, ensure consistent product standards, and expedite drug development and approval processes. Their endorsement stems from the method's capacity to enhance process control and product quality monitoring, thus minimizing variations. By encouraging its adoption, regulatory bodies aim to modernize manufacturing practices, boost efficiency, and maintain stringent quality standards across the pharmaceutical industry, thereby fostering market growth and widespread adoption.

• Increased Efficiency and Productivity by Continuous Manufacturing Processes

Continuous manufacturing processes transform efficiency in pharmaceutical production by drastically cutting production cycle times, minimizing manual interventions, and boosting overall productivity in contrast to traditional batch manufacturing. By streamlining operations and eliminating batch-related downtimes, continuous processes ensure seamless production flows and rapid product turnaround. Automation and real-time monitoring further enhance efficiency, enabling immediate adjustments and quality assurance measures. Consequently, pharmaceutical companies can meet market demands swiftly, reduce costs, and maintain high-quality standards, enhancing competitiveness in the industry.

Restraints/Challenges

• Risk of Technology Failure Impact Production Efficiency

Continuous manufacturing systems are reliant on automation, control systems, and software platforms, which may be prone to technical glitches, software failures, or equipment malfunctions. The risk of technology failure and process disruptions can impact production efficiency, product quality, and regulatory compliance, posing risks to patient safety and business continuity.

• Initial Investment Costs

Implementing continuous manufacturing requires significant upfront investment in equipment, technology upgrades, staff training, and process validation. The high initial costs associated with transitioning from traditional batch manufacturing to continuous processes may deter some pharmaceutical companies from adopting these technologies.

This global pharmaceutical continuous manufacturing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global pharmaceutical continuous manufacturing market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In March 2022, USP India extended its presence in Hyderabad, announcing plans for a new continuous manufacturing facility with an added capital injection of USD 20 million. This expansion underscores USP's commitment to enhancing its operations and services in India's pharmaceutical sector
• In March 2022, Phlow Corp, a U.S. based public benefit company specializing in essential medicines, partnered with Virginia Commonwealth University (VCU) Medicines for All Institute and AMPAC Fine Chemicals. The collaboration aims to offer contract research and development services for small molecule pharmaceutical products, focusing on continuous manufacturing, thereby bolstering the pharmaceutical industry's capabilities and innovation

Global Pharmaceutical Continuous Manufacturing Market Scope

The global pharmaceutical continuous manufacturing market is segmented into four notable segments based on product type, application type, distribution channel, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Integrated Systems
•  Semi-Continuous Systems
• Controls
• Continuous Granulators
• Continuous Coaters
• Continuous Blenders
• Continuous Dryers
• Other semi-continuous Systems

Application Type

•  Active Pharmaceutical Ingredient
•  Dry Powders
• Biologics
• End Product Manufacturing
• Solid Dosage

Distribution Channel

• Retail Pharmacy
• Online Pharmacy
• Hospital Pharmacy

End User

• Research and Development Departments
•  Full-Scale Manufacturing Companies
• Contact Manufacturing Organizations (CMOs)
• Pharmaceuticals Companies
• Research Institutes
• Contact Research Organizations (CROs)

Global Pharmaceutical Continuous Manufacturing Market Regional Analysis/Insights

The global pharmaceutical continuous manufacturing market is analysed and market size insights and trends are provided by based on product type,  application type,  distribution channel, and end user as referenced above.

The countries covered in the global pharmaceutical continuous manufacturing market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.

Europe dominates the global pharmaceutical continuous manufacturing market due to its stringent regulatory environment, fostering innovation and adoption of advanced manufacturing techniques. The region boasts a well-established pharmaceutical industry, extensive research infrastructure, and strong support for technological development.

Asia-Pacific is the fastest-growing region in the global pharmaceutical continuous manufacturing market due to increasing investments in pharmaceutical manufacturing infrastructure, rising adoption of advanced technologies, expanding pharmaceutical markets, growing demand for affordable healthcare solutions, and supportive government initiatives promoting innovation and development in the region.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Pharmaceutical Continuous Manufacturing Market Share Analysis

The global pharmaceutical continuous manufacturing market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global pharmaceutical continuous manufacturing market.

Some of the major players operating in the global pharmaceutical continuous manufacturing market are:

• GEA Group Aktiengesellschaft (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• Hosokawa Micron B.V. (Japan)
• Robert Bosch GmbH 9Germeany)
• Glatt GmbH (India)
• Siemens (Germany)
• Coperion GmbH (Germany)
• Aurobindo Pharma (India)
• L.B. Bohle Maschinen und Verfahren GmbH (Germany)
• Dr. Reddy’s Laboratories Ltd. (India)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Sanofi (France)

SKU-60039